Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870295 | 0.94 | ABHD6 (0.42) | MEN1KMT2ATAAR1POLBABHD6 | |
| SCHEMBL5870424 | 0.85 | HDAC8 (0.41) | CTSKMEN1KMT2ACTSLCTSS | |
| SCHEMBL5870547 | 0.80 | HDAC8 (0.45) | MEN1KMT2APOLBABHD6NLRP3 | |
| SCHEMBL5870349 | 0.71 | SMN1; SMN2 (0.35) | CTSKCTSLCTSSPOLB | |
| SCHEMBL5870592 | 0.71 | TSHR (0.37) | CTSKMEN1KMT2ATAAR1CTSL | |
| SCHEMBL5870405 | 0.69 | CTSS (0.39) | CTSKCTSLCTSSCTSB | |
| SCHEMBL5870440 | 0.67 | OPRM1 (0.33) | CTSKCTSLCTSSCTSB | |
| SCHEMBL8610388 | 0.66 | ABHD6 (0.56) | MEN1KMT2ATAAR1ABHD6NLRP3 | |
| SCHEMBL5870292 | 0.66 | ABHD6 (0.42) | MEN1KMT2ATAAR1ABHD6 | |
| SCHEMBL7915917 | 0.65 | NOTUM (0.55) | ABHD6DPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSK 58/4885MEN1 2979/4885KMT2A 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.